Liquidia Q3: YUTREPIA Sales $222.7M, Adjusted EBITDA $140.5M, October Shipments at Record
LQDA has more than doubled off its 52-week low of $22.31.
Summary
Liquidia's Q3 revenue hit $222.7 million with adjusted EBITDA of $140.5 million, and October shipments set a record — the loss was purely the $389.7 million United Therapeutics settlement charge.
Key Events · Earnings and Guidance · LQDA
-
YUTREPIA Sales Reach $222.7M
Q3 2026 net product sales of $222.7 million versus $51.7 million a year earlier, up 31% from Q2 2026; paid patient demand was $212.2 million.
-
Adjusted EBITDA $140.5M, Fifth Straight Gain
Non-GAAP adjusted EBITDA rose to $140.5 million from $96.3 million in Q2 2026, a 46% sequential increase; GAAP net loss of $236.3 million reflects the $389.7 million settlement charge.
-
October Shipments Hit Record High
Total patient shipments in October 2026 were the highest since launch, the prescriber base reached 1,300, and the daily referral rate was more than 75% of the Q3 pace.
-
Cash $396.1M Against $380.7M Settlement
Cash and cash equivalents were $396.1 million at September 30, 2026, before settlement payments; net $380.7 million is payable in installments in 2026 and 2027, and stockholders' equity was a $25.4 million deficit.
Analysis · LQDA · Life Sciences
The commercial ramp is still accelerating rather than plateauing: YUTREPIA net product sales of $222.7 million rose 31% quarter over quarter, and adjusted EBITDA climbed to $140.5 million, the fifth straight quarterly increase. The $236.3 million net loss is entirely the $389.7 million litigation settlement charge, not operating deterioration; excluding it, the business is solidly profitable on a non-GAAP basis. First look at post-settlement demand comes from the new October data — record monthly shipments, 1,300 prescribers, and a referral rate above 75% of the Q3 pace — and it shows no disruption from the PH-ILD label removal. The balance sheet is the caveat: $396.1 million of cash against a $25.4 million stockholders' deficit, with $380.7 million of settlement payments still to be made in 2026 and 2027.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 47.7% of the 1624 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LQDA was trading at $47.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $22.31 to $93.61. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.